For research use only. Not for therapeutic Use.
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC50 of 1-5 μM in vitro[1].
D-erythro-MAPP (D-e-MAPP) reduces the viability of MCF-7 cells in a dose-dependent manner with IC50 value of 4.4 μM, and 15.6 μM, respectively[1].
D-erythro-MAPP (D-e-MAPP) induces G0/G1 arrest in cell cycle progression resulting in growth suppression[2].
| Catalog Number | R043497 |
| CAS Number | 143492-38-0 |
| Synonyms | N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]tetradecanamide |
| Molecular Formula | C23H39NO2 |
| Purity | ≥95% |
| InChI | InChI=1S/C23H39NO2/c1-3-4-5-6-7-8-9-10-11-12-16-19-22(25)24-20(2)23(26)21-17-14-13-15-18-21/h13-15,17-18,20,23,26H,3-12,16,19H2,1-2H3,(H,24,25)/t20-,23-/m1/s1 |
| InChIKey | YLAZEWZHIRBZDA-NFBKMPQASA-N |
| SMILES | CCCCCCCCCCCCCC(=O)NC(C)C(C1=CC=CC=C1)O |
| Reference | [1]. Hüseyin İzgördü, et al. Characteristics of apoptosis induction in human breast cancer cells treated with a ceramidase inhibitor. Cytotechnology. 2020 Dec;72(6):907-919. [2]. A Bielawska, et al. (1S,2R)-D-erythro-2-(N-myristoylamino)-1-phenyl-1-propanol as an inhibitor of ceramidase. J Biol Chem. 1996 May 24;271(21):12646-54. |
